Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Cash & Current Investments: 2016-2025

Historic Cash & Current Investments for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to $425.2 million.

  • Ultragenyx Pharmaceutical's Cash & Current Investments fell 31.59% to $425.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year decrease of 15.05%. This contributed to the annual value of $610.0 million for FY2024, which is 5.69% up from last year.
  • Per Ultragenyx Pharmaceutical's latest filing, its Cash & Current Investments stood at $425.2 million for Q3 2025, which was down 12.78% from $487.6 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's 5-year Cash & Current Investments high stood at $965.4 million for Q1 2021, and its period low was $412.1 million during Q1 2024.
  • For the 3-year period, Ultragenyx Pharmaceutical's Cash & Current Investments averaged around $546.9 million, with its median value being $552.0 million (2023).
  • Its Cash & Current Investments has fluctuated over the past 5 years, first skyrocketed by 45.55% in 2021, then slumped by 50.25% in 2023.
  • Ultragenyx Pharmaceutical's Cash & Current Investments (Quarterly) stood at $740.2 million in 2021, then grew by 1.02% to $747.8 million in 2022, then dropped by 22.81% to $577.2 million in 2023, then grew by 5.69% to $610.0 million in 2024, then crashed by 31.59% to $425.2 million in 2025.
  • Its last three reported values are $425.2 million in Q3 2025, $487.6 million for Q2 2025, and $494.4 million during Q1 2025.